☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Out-Licensing Agreement
CStone Signs an Out-Licensing Agreement with EQRx for Sugemalimab and CS1003
October 27, 2020
Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis
October 7, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.
